BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane.

被引：0
|
作者：
Moreno-Aspitia, A.
Hillman, D. W.
Wiesenfeld, M.
Hobday, T. J.
Rowland, K. M.
Northfelt, D. W.
Tenner, K. S.
Palmieri, F. M.
Perez, E. A.
机构：
[1] Mayo Clin, Jacksonville, FL 32224 USA
[2] Mayo Clin, Rochester, MN USA
[3] Oncol Associates, Cedar Rapids, IA USA
[4] Carle Canc Ctr, Urbana, IL USA
[5] Mayo Clin Scottsdale, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：22S / 22S
页数：1
相关论文
共 50 条
  • [31] Phase II study of navelbine plus carboplatin followed by oral navelbine in patients with metastatic/recurrent triple negative breast cancer previously treated with anthracycline and taxane
    El-Sadda, W.
    Halim, I. Abdel
    El-Ibrashi, M.
    CANCER RESEARCH, 2017, 77
  • [32] Phase II study of bay 43-9006 (SORAFENIB) in patients with chemo-naive hormone refractory prostate cancer (HRPC)
    Chi, Kim N.
    Ellard, Susan
    Hotte, Sebastien J.
    Czaykowski, Piotr
    Moore, Malcolm
    Ruether, Joseph Dean
    Hansen, Clive
    Seymour, Lesley
    ANNALS OF ONCOLOGY, 2006, 17 : 152 - 152
  • [33] Phase II study of single agent oral vinorelbine as a first line treatment for postmenopausal patients with locally recurrent or metastatic breast cancer previously treated with anthracycline or taxanes
    Elebrashi, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S113 - S113
  • [34] A phase II study of BAY 43-9006 in patients with androgen-independent prostate cancer (AIPC) with proteomic profiling.
    Posadas, EM
    Gulley, J
    Arlen, PM
    Harold, N
    Fioravanti, S
    Meltzer, P
    Scripture, CD
    Figg, WD
    Kohn, EC
    Dahut, WL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 443S - 443S
  • [35] Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma
    Gollob, J. A.
    Moran, K.
    Richmond, T.
    Jones, J. M.
    Baell, T. E.
    Rathmell, W. K.
    Peterson, B. L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 227
  • [36] Therapeutic options for patients with anthracycline- and taxane-refractory metastatic breast cancer
    Hille, S.
    Rein, D. T.
    Dall, P.
    Breidenbach, M.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2007, 67 (12) : 1311 - 1316
  • [37] Capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer
    S.-H. Lee
    J. Lee
    J. Park
    S. H. Park
    K.-E. Lee
    S. I. Lee
    E. Nam
    J. O. Park
    K. Kim
    C. W. Jung
    Y. S. Park
    S. S. Yoon
    W. K. Kang
    M. H. Lee
    K. Park
    Y.-H. Im
    Medical Oncology, 2004, 21 : 223 - 231
  • [38] Treatment strategies for patients with anthracycline- and taxane-pretreated metastatic breast cancer
    Seidman, Andrew D.
    SEMINARS IN ONCOLOGY, 2008, 35 (02) : A3 - A4
  • [39] Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
    Lee, SH
    Lee, J
    Park, J
    Park, SH
    Lee, KE
    Lee, SI
    Nam, E
    Park, JO
    Kim, K
    Jung, CW
    Park, YS
    Yoon, SS
    Kang, WK
    Lee, MH
    Park, K
    Im, YH
    MEDICAL ONCOLOGY, 2004, 21 (03) : 223 - 231
  • [40] Ixabepilone in patients (PTS) with metastatic breast cancer (MBC) that is resistant to an anthracycline, a taxane and capecitabine
    Pivot, Xavier
    Thomas, Eva
    Lerzo, Guillermo
    Bosserman, Linda
    Vahdat, Linda
    Cai, Can
    Mullaney, Brian
    Viens, Patrice
    Perez, Edith
    Hortobagyi, Gabriel N.
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 71
12345